CLINICAL TRIALS PROFILE FOR LEVEMIR FLEXPEN
✉ Email this page to a colleague
All Clinical Trials for LEVEMIR FLEXPEN
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00655200 ↗ | Observational Study of Safety and Tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the Treatment of Type 1 and Type 2 Diabetes Mellitus | Completed | Novo Nordisk A/S | 2008-02-01 | This study is conducted in Asia. The aim of this observational study is to evaluate the safety and tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the treatment of Filipino patients with Type 1 and Type 2 Diabetes Mellitus. | |
NCT00670683 ↗ | Observational Study of Patients With Diabetes Using Levemir® FlexPen® | Completed | Novo Nordisk A/S | 2007-07-01 | This study is conducted in Asia. This study is a prospective, open, uncontrolled, observational surveillance study with Levemir® FlexPen® conducted in Korea. The aim of this observational study is to evaluate the short term and the long term safety and efficacy of Levemir® FlexPen®. The study is planned and conducted as per requirement from Korea Food and Drug Administration (KFDA). | |
NCT00906529 ↗ | Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin | Withdrawn | Novo Nordisk A/S | Phase 4 | 2009-05-01 | The purpose of this study is to determine whether aggressive (goal pre-prandial blood glucose <110 mg/dl) versus conservative (goal pre-prandial blood glucose <180mg/dl) diabetes treatment of type 2 diabetic patients on the general medical wards has any effect on hospital outcomes. |
NCT00906529 ↗ | Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin | Withdrawn | University of Texas Southwestern Medical Center | Phase 4 | 2009-05-01 | The purpose of this study is to determine whether aggressive (goal pre-prandial blood glucose <110 mg/dl) versus conservative (goal pre-prandial blood glucose <180mg/dl) diabetes treatment of type 2 diabetic patients on the general medical wards has any effect on hospital outcomes. |
NCT01420692 ↗ | The Effects of Insulin Detemir and Gliclazide-MR Treatments on Endothelial Functions in Patients With Type 2 Diabetes | Completed | Hacettepe University | N/A | 2010-06-01 | The main purpose of this study is to analyze the effects of the addition of sulfonylurea (gliclazide MR) or ,alternatively, basal insulin (insulin detemir) to life-style modification and metformin treatment as a second step treatment in type 2 diabetes mellitus on endothelial cell functions. The second goal is to identify the effects of these treatment alternatives on body-mass index, the changes in body fat mass, insulin resistance and on the insulin secretion capacity of beta cells. The third aim of this study is to determine the success rates of these treatment alternatives on glycemic control at 6 months follow-up. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LEVEMIR FLEXPEN
Condition Name
Clinical Trial Locations for LEVEMIR FLEXPEN
Trials by Country
Clinical Trial Progress for LEVEMIR FLEXPEN
Clinical Trial Phase
Clinical Trial Sponsors for LEVEMIR FLEXPEN
Sponsor Name